An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors (NCT07222267)

🧪 Interventions in This Study

• BG-75202 (DRUG)
• CDK4 Inhibitor (DRUG)
• Estrogen Receptor Antagonist (DRUG)
• Aromatase Inhibitor (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (31 Sites)

Showing the first 25 of 31 sites.

• University of Alabama At Birmingham Hospital — Birmingham, Alabama
• Yale Cancer Center — New Haven, Connecticut
• Washington University in St Louis — St Louis, Missouri
• Next Oncology Austin — Austin, Texas
• The University of Texas Md Anderson Cancer Center — Houston, Texas
• Fred Hutchinson Cancer Research Center — Seattle, Washington
• Blacktown Cancer and Haematology Centre — Blacktown, New South Wales
• Chris Obrien Lifehouse — Camperdown, New South Wales
• Cancer Research South Australia — Adelaide, South Australia
• Austin Health — Heidelberg, Victoria
• Peter Maccallum Cancer Centre — Melbourne, Victoria
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality
• Beijing Cancer Hospital — Beijing, Beijing Municipality
• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality
• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian
• Sun Yat Sen University Cancer Center Huangpu Branch — Guangzhou, Guangdong
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
• Jiangsu Province Hospital Longjiang Branch — Nanjing, Jiangsu
• Fudan University Shanghai Cancer Centerpudong — Shanghai, Shanghai Municipality
• Tianjin Medical University Cancer Institute and Hospital — Tianjin, Tianjin Municipality
• Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang
• Istituto Europeo Di Oncologia — Milan,
• Istituto Nazionale Tumori Fondazione G Pascale — Naples,
• Fondazione Policlinico Universitario Agostino Gemelli — Roma,
• Istituto Clinico Humanitas — Rozzano,

📞 Contact the Study Coordinator

Phone: (877) 828-5568

Email: clinicaltrials@beonemed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer

• S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
• Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
• A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
• ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California

Explore by condition: All Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.